ANCY TOM: Open Payments
NPI 1669840203 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,887 in 177 payments from 18 companies in 2025. Trend: 2023 $683 · 2024 $1,952 · 2025 $3,887
Food & beverage: $3,776Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $539 |
| Otsuka America Pharmaceutical, Inc. | 27 | $528 |
| E.R. Squibb & Sons, L.L.C. | 17 | $437 |
| ABBVIE INC. | 22 | $408 |
| Alkermes, Inc. | 13 | $343 |
| Teva Pharmaceuticals USA, Inc. | 14 | $326 |
| Vanda Pharmaceuticals Inc. | 10 | $293 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $267 |
| Neurocrine BioSciences, Inc. | 10 | $177 |
| Lundbeck LLC | 12 | $175 |
Products named: REXULTI, CAPLYTA, COBENFY, VRAYLAR, ARISTADA, FANAPT, RELISTOR, INGREZZA.
Industry payments across NV — which companies pay providers there.
